Alumis
Manufacturing · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
280 E Grand Ave, South San Francisco, Ca...Phone Number
(650) 231-6625Website
www.alumis.comRevenue
$8.4 MillionStock Symbol
ALMSIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Alumis
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.Explore more
Alumis Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Alumis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Alumis is spiking on competitors!
Alumis, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Alumis recently announced quarterly report
Click to see if Alumis had a recent Job posting/layoffs
Product Launch: Get notified when Alumis launches new products
Check if Alumis has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Alumis
Funding: Get notified immidiatlly once Alumis has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Alumis
Compare insights from companies similar to Alumis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Alumis is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Alumis is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Alumis.
Alumis financials insights
Gather financial insights about Alumis, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Series C
$259M
Stock Offering
$250M
Alumis Tech Stack
A closer look at the technologies used by Alumis
Most Recent Scoops
Person-Based
Medical Research, Pharmaceuticals
Open Position
Open Position
Open Position
Person-Based
Medical Research
Alumis News & Media
Alumis’ lupus drug heads to Phase III despite mid-stage miss
If envudeucitinib were to secure approval in SLE, it could become one of the first oral targeted therapies to reach the market.Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven Diseases Transcript
Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven Diseases September 1, 2026 8:30 AM EDTCompany...Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)
Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements
– ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envudeucitinib to set a new standard in PsO –
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Alumis
Sign Up For FreeTo access detailed company insights
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-pe... Read More
